Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2690-2698

  Braun, Michael S ^a   Richman, Susan D ^a   Quirke, Philip ^a   Daly, Catherine ^a   Adlard, Julian W ^a   Elliott, Faye ^a   Barrett, Jennifer H ^a   Selby, Peter ^a   Meade, Angela M ^a   Stephens, Richard J ^a   Parmar, Mahesh K B ^a   Seymour, Matthew T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PROTEIN MLH1; PROTEIN P53; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COLORECTAL TUMOR; FEMALE; MALE; MIDDLE AGED; PREDICTION AND FORECASTING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 45749127481     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5580     Document Type: Article

References (43)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
3. National Institute for Health and Clinical Excellence (NICE): Final appraisal determination: Bevacizumab and cetuximab for metastatic colorectal cancer. http://www.nice.org.uk/page.aspx?o=353402
4. McShane LM, Altman DG, Sauerbrei W, et al: and Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics: Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387-391, 2005
5. Barratt PL, Seymour MT, Stenning SP, et al: and the AXIS Collaborators: DNA markers predicting benefit from adjuvant 5-fluorouracil in colon cancer patients: A molecular study. Lancet 360:1381-1391, 2002
6. Grabsch H, Kerr D, Quirke P: Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? Histopathology 45:312-334, 2004
7. Munro AJ, Lain S, Lane DP: p53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 92:434-444, 2005
8. Seymour MT, Maughan TS, Ledermann JA, et al: for the FOCUS Trial Investigators and the National Cancer Res Institute Colorectal Clinical Studies Group: Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007
9. Cheeseman SL, Joel SP, Chester JD, et al: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87:393-399, 2002
10. Leonard P, Seymour MT, Janes R, et al: Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. Br J Cancer 87:1216-1220, 2002
11. Braun MS, Adab F, Bradley C, et al: Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. Br J Cancer 89:1155-1158, 2003
12. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316, 1998
13. McLeod HL, Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Br J Cancer 74:508-512, 1996
14. Magrini R, Bhonde MR, Hanski ML, et al: Cellular effects of CPT-11 on colon carcinoma cells: Dependence on p53 and hMLH1 status. Int J Cancer 101:23-31, 2002
15. Okamoto R, Takano H, Okamura T, et al: O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives. Jpn J Cancer Res 93:93-102, 2002
16. Trifan OC, Durham WF, Salazar VS, et al: Cyclooxygenase-2 inhibition with celecoxib enhances antitumour efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62:5778-5784, 2002
17. Cawkwell L, Gray S, Murgatroyd H, et al: Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 45:409-415, 1999
18. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst 94:936-942, 2002
19. Sai K, Kaniwa N, Itoda M, et al: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13:741-757, 2003
20. Illmer T, Schuler US, Thiede C, et al: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 62:4955-4962, 2002
21. Park SY, Lam W, Cheng YC: X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62:459-465, 2002
22. Stoehlmacher J, Ghaderi V, Iobal S, et al: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079, 2001
23. Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658, 2001
24. McLeod HL, Sargent DJ, Marsh S, et al: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer: Results from an intergroup trial. Proc Am Soc Clin Oncol 22:253s, 2003 (suppl; abstr 1013)
25. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
26. Richman SD, Braun MS, Adlard JW, et al: Prognostic value of thymidylate synthase expression on failure-free survival of fluorouracil-treated metastatic colorectal cancer patients. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 24:543s, 2006 (suppl 18S; abstr 10011)
27. Gönen M: Planning for subgroup analysis: A case study of treatment-marker interaction in metastatic colorectal cancer. Control Clin Trials 24:355-363, 2003
28. Wacholder S, Chanock S, Garcia-Closas M, et al: Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442, 2004
29. Boonsong A, Curran S, McKay JA, et al: Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 33:1114-1119, 2002
30. Paradiso A, Xu J, Mangia A, et al: Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111:252-258, 2004
31. Pommier Y, Pourquier P, Urasaki Y, et al: Topoisomerase I inhibitors: Selectivity and cellular resistance. Drug Resist Updat 2:307-318, 1999
32. Pavillard V, Charasson V, Laroche-Clary A, et al: Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan: A preliminary study. Anticancer Res 24:579-585, 2004
33. Vallböhmer D, Iqbal S, Yang DY, et al: Molecular determinants of irinotecan efficacy. Int J Cancer 119:2435-2442, 2006
34. van Waardenburg RC, de Jong LA, van Eijndhoven MA, et al: Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem 279:54502-54509, 2004
35. Juan CC, Hwang JL, Liu AA, et al: Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci U S A 85:8910-8913, 1988
36. Korn WM, Yasutake T, Kuo WL, et al: Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25:82-90, 1999
37. Aragane H, Sakakura C, Nakanishi M, et al: Chromosomal aberrations in colorectal cancers and liver metastases analyzed by comparative genomic hybridization. Int J Cancer 94:623-629, 2001
38. Postma C, Hermsen MA, Coffa J, et al: Chromosomal instability in flat adenomas and carcinomas of the colon. J Pathol 205:514-521, 2005
39. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
40. Ribic CM, Sargent DJ, Moore MJ, et al: Tumour microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
41. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 370:135-142, 2007
42. Seymour MT, Maughan TS, Wasan HS, et al: Capecitabine and oxaliplatin in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial. J Clin Oncol 25:500s, 2007 (suppl; abstr 9030)
43. Amado RG, Wolf M, Freeman D, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008